UNC-Chapel Hill researchers use light to launch drugs from red blood cells

January 04, 2017

Scientists at the University of North Carolina at Chapel Hill have developed a breakthrough technique that uses light to activate a drug stored in circulating red blood cells so that it is released exactly when and where it is needed.

The work, led by Fred Eshelman Distinguished Professor David Lawrence in the Eshelman School of Pharmacy, has profound implications for the field of drug delivery by using red blood cells to carry drugs and then using light to release them in precise locations. The technique, which overcomes a decades-long scientific hurdle, could drastically reduce the amount of a drug needed to treat disease and thus side effects.

"Using light to treat a disease site has a lot of benefits beyond the isn't-that-cool factor," said Lawrence, whose work is published in the journal Angewandte Chemie. "Those benefits could include avoiding surgery and the risk of infection, making anesthesia unnecessary and allowing people to treat themselves by shining a light on a problem area, such as an arthritic knee."

Lawrence and his team attached a drug molecule to vitamin B12 and loaded the compound into red blood cells, which can circulate for up to four months, providing a long-lasting reservoir of medicine that can be tapped as needed. They then demonstrated their ability to overcome a longtime technical hurdle: using long-wavelength light to penetrate deep enough into the body to break molecular bonds; in this case, the drug linked to vitamin B12.

Here's the rub: Long-wavelength light can penetrate much more deeply into the body, but it doesn't carry as much energy as short wavelength light, and cannot typically break molecular bonds. To activate the drug with long-wavelength light, Lawrence and his team had to figure out how to do it in a way that required less energy.

"That's the trick, and that's where we've been successful," said Lawrence.

Lawrence's team solved the energy problem by introducing a weak energy bond between vitamin B12 and the drug and then attached a fluorescent molecule to the bond. The fluorescent molecule acts as an antenna, capturing long wavelength light and using it to cut the bond between the drug and the vitamin carrier.

Lawrence pointed to some complex and deadly cancers where physicians might have a better chance of helping the patient if a wide array of anti-cancer agents could be used.

"The problem is when you start using four or five very toxic drugs you're going to have intolerable side effects," he said. "However, by focusing powerful drugs at a specific site, it may be possible to significantly reduce or eliminate the side effects that commonly accompany cancer chemotherapy."

Lawrence has also created a company in partnership with UNC, Iris BioMed, to further develop the technology to be used in humans. Lawrence is a member of the UNC Lineberger Comprehensive Cancer Center and professor in the College of Arts and Sciences and School of Medicine.
-end-


University of North Carolina at Chapel Hill

Related Red Blood Cells Articles from Brightsurf:

SMART researchers develop fast and efficient method to produce red blood cells
Researchers from Singapore-MIT developed a faster and more efficient way to manufacture red blood cells that cuts down on cell culture time by half.

Synthetic red blood cells mimic natural ones, and have new abilities
Scientists have tried to develop synthetic red blood cells that mimic the favorable properties of natural ones, such as flexibility, oxygen transport and long circulation times.

Exeter student leads research concluding that small red blood cells could indicate cancer
Having abnormally small red blood cells - a condition known as microcytosis - could indicate cancer, according to new research led by a University of Exeter student working with a world-leading team.

Physicists design 'super-human' red blood cells to deliver drugs to specific targets
A team of physicists from McMaster University has developed a process to modify red blood cells so they can be used to distribute drugs throughout the body, which could specifically target infections or treat catastrophic diseases such as cancer or Alzheimer's.

Blood transfusions: Fresh red blood cells no better than older ones
Findings from the ABC-PICU study on critically ill children may alter policies at hospitals where fresh red cells are preferentially used.

Fresh red blood cell transfusions do not help critically ill children more than older cells
Researchers have found that transfusions using fresh red blood cells -- cells that have spent seven days or less in storage -- are no more beneficial than older red blood cells in reducing the risk of organ failure or death in critically ill children.

Red blood cell donor pregnancy history not tied to mortality after transfusion
A new study has found that the sex or pregnancy history of red blood cell donors does not influence the risk of death among patients who receive their blood.

How sickled red blood cells stick to blood vessels
An MIT study describes how sickled red blood cells get stuck in tiny blood vessels of patients with sickle-cell disease.

Novel gene in red blood cells may help adult newts regenerate limbs
Adult newts can repeatedly regenerate body parts. Researchers from Japan, including the University of Tsukuba, and the University of Daytona, have identified Newtic1, a gene that is expressed in clumps of red blood cells in the circulating blood.

Healthy red blood cells owe their shape to muscle-like structures
The findings could shed light on sickle cell diseases and other disorders where red blood cells are deformed.

Read More: Red Blood Cells News and Red Blood Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.